Print
Hits: 6409
The Economic Times
08 June 2012

HYDERABAD: Dr Reddy's Laboratories has launched in the US market ropinirole hydrochloride XR (extended release) tablets used to treat the signs and symptoms of Parkinson's disease.

Ropinirole hydrochloride XR tablets are the bioequivalent generic version of Requip XL tablets, a registered trademark of pharma giant SmithKline Beecham.

The Indian company has obtained the approval of the United States Food and Drug Administration for its abbreviated new drug application for ropinirole hydrochloride XR tablets to launch a generic product. Requip XL had reported sales of around $58 million for the 12 months period ended March 2012 in the US market according to IMS Health.

Dr Reddy's said its ropinirole hydrochloride XR tablets in 2 mg, 4 mg and 6 mg will be available in 30 and 90 count bottle sizes, 8 mg and 12 mg in 30 count bottle sizes

Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ’Fair dealing’ or ’Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.